Prelude Therapeutics Incorporated
preludetx.comWhat Do They Do?
Develops targeted cancer medicines for patients with underserved cancers, including drugs designed to block or break down cancer-driving proteins and antibody-linked medicines.
10-K for FY2025, filed Mar 10, 2026Prelude Therapeutics Incorporated ("Prelude" or the "Company") is a precision oncology company built on a foundation of drug discovery…View ↗
By focusing on developing molecules using broad mechanisms that have multiple links to oncogenic driver pathways in select patients, we…View ↗
We leverage multiple modalities (inhibitors, degraders, and antibody-drug conjugates) in order to deliver clinical candidates that meet our…View ↗
Focus on targets that allow us to select patients and cancers with high unmet need with no approved therapies, or patient populations that…View ↗
How Do They Make Money?
Prelude receives upfront payments for licensing degrader antibody-conjugate programs and may earn further milestone payments and royalties on product sales. A partner also paid for an option to acquire rights to a cancer-drug program, with additional milestones and royalties possible if the option is exercised.
10-K for FY2025, filed Mar 10, 2026
$12.1M
-
10-K for FY2025, filed Mar 10, 2026
$12.1M ↗
Who Are Their Customers?
Drug-company partners work with Prelude on antibody-linked cancer-drug programs. AbCellera leads manufacturing and Prelude leads clinical development and commercialization in their joint programs; AbCellera also licenses selected programs, while Incyte holds an option to acquire rights to a cancer-drug program.
10-K for FY2025, filed Mar 10, 2026In 2023, we entered into a multi-year, multi-program agreement with AbCellera Biologics Incorporated ("AbCellera") to jointly discover…View ↗
During the third quarter of 2025 we amended our collaboration with AbCellera (the "Amended Agreement") and, subsequently in October 2025…View ↗
This program is the subject of an Exclusive Option Agreement (the “Option Agreement”) with Incyte Corporation (“Incyte”) as announced on…View ↗
Do Revenues Turn Into Profits?
No. It lost $99.5M in FY2025.
10-K for FY2025, filed Mar 10, 2026
−$104.6MView ↗
10-K for FY2025, filed Mar 10, 2026
−$99.5MView ↗
10-K for FY2025, filed Mar 10, 2026
−$56.4MView ↗
How Are They Changing?
A changed drug pipeline
The earlier report described inhibitors and a SMARCA protein degrader as key programs. The latest emphasizes a mutation-targeting inhibitor, a selective protein degrader and antibody-linked drug programs, and says clinical work on the SMARCA degrader program is paused.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Mar 10, 2026PRT12396, our lead, mutant-selective JAK2V617F inhibitor received IND clearance from the U.S. FDA, as announced in February 2026 and we…View ↗
We have selected a development candidate and remain on track to file an IND in mid-2026 with Phase 1 study initiation anticipated in the…View ↗
In 2023, we entered into a multi-year, multi-program agreement with AbCellera Biologics Incorporated ("AbCellera") to jointly discover…View ↗
On November 4, 2025 we announced that we decided to pause the clinical development of our SMARCA2 degrader program which is comprised of…View ↗
More partner licensing
The older report described a wholly owned, internally developed pipeline. The latest includes licensed antibody-linked drug programs and an option for a partner to acquire rights to a cancer-drug program.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Mar 10, 2026We are a clinical-stage fully integrated oncology company built on a foundation of drug discovery excellence to deliver novel precision…View ↗
Who Do They Compete With?
Competes with Ajax Therapeutics, Atavistik Bio, Cogent Biosciences, Eilean Therapeutics, Incyte, Llydlaw Therapeutics, Rathyra Therapeutics, V6 Therapeutics, Pfizer, Olema Oncology, Menarini Group, BeOne Medicines, Ideaya Biosciences, Isosterix, ProtAI, and Beijing Konruns Pharmaceutical
10-K for FY2025, filed Mar 10, 2026For our JAK2V617F inhibitor program, competition includes Ajax Therapeutics, Atavistik Bio, Cogent Biosciences, Eilean Therapeutics, Incyte…View ↗
Loading...
